Anticoagulation Therapy of Atrial Fibrillation in the Elderly
The prevalence of atrial fibrillation (AF) increases substantially with age. The most recent data come from a cross-sectional study of adults in California, dealing with a population of 1.89 million . The overall prevalence of AF was 0.95%; prevalence increased from 0.1% among adults younger than 55 years to 4.0% in subjects older than 60 years and up to 9.0% in persons aged 80 years or older. The authors estimate that approximately 2.3 million adults in the United States currently have AF, and project that this figure will increase to more than 5.6 million by the year 2050, with more than 50% of affected individuals aged 80 years or older. The estimate for AF in Italy is about 500 000 subjects, with an incidence of 60.000 new cases per year.
KeywordsAtrial Fibrillation Stroke Prevention Atrial Fibrillation Patient Antithrombotic Therapy Mitral Valve Disease
Unable to display preview. Download preview PDF.
- 3.Hart RG, Pearce LA, McBride R et al, on behalf of the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators (1999) Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation. Analysis of 2012 participants in the SPAF I-III clinical trials. Stroke 30:1223–1229PubMedCrossRefGoogle Scholar
- 7.Di Pasquale G, Cerè E, Biancoli S et al (2002) Antiplatelet agents for prevention of thromboembolism in atrial fibrillation: when, why, and which one? In: Raviele A (ed) Cardiac Arrhythmias 2001. Springer, Milan, pp 422–435Google Scholar
- 11.Stroke Prevention in Atrial Fibrillation Investigators (1994) Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343:687–691Google Scholar
- 16.Pengo V, Legnani C, Noventa F, Palareti G, on behalf of the ISCOAT Study Group (2001) Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. Thromb Haemost 85:418–422Google Scholar